GlassScriptPhysician profile
Katay C Bouttamy
NPI 1558315721
$13,619.85
in general payments reported to CMS, 2019-2025
50 companies · $2,611 in 2025
The $2,611 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $1,227 · 2021: $1,585 · 2022: $1,942 · 2023: $2,524 · 2024: $2,549 · 2025: $2,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,665 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,664.67 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,841.93 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,585.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,558.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $972.65 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $686.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $659.55 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $611.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $586.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $399.93 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $367.44 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Sanofi-Aventis U.S. LLC | $336.97 | 2019-2023 | |
| Preventric Diagnostics, INC. | $290.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $254.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.24 | 2019-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $235.97 | 2019-2025 | Zoryve |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $235.31 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $214.83 | 2023-2025 | Gemtesa |
| Amgen INC. | $207.51 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $190.48 | 2019-2022 | |
| Allergan, INC. | $188.87 | 2019-2020 | |
| Amarin Pharma, INC. | $152.99 | 2019-2022 | |
| Abbott Laboratories | $150.26 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $150.14 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.30 | 2019-2024 | |
| Corium, LLC | $134.01 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.86 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $110.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $94.42 | 2023-2025 | Accrufer |
| Lundbeck LLC | $94.29 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $92.00 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $76.35 | 2023-2024 | Rexulti, Abilify Maintena |
| Viatris Specialty LLC | $73.45 | 2025 | Yupelri |
| Tris Pharma INC | $61.81 | 2023-2024 | Dyanavel Xr |
| Genentech USA, INC. | $57.21 | 2019-2020 | |
| Axsome Therapeutics, INC. | $53.24 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $50.19 | 2020-2025 | Austedo Xr |
| Edwards Lifesciences Corporation | $39.53 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $30.55 | 2023 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $28.66 | 2025 | Zenpep |
| Tonix Medicines, INC. | $28.14 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $27.85 | 2019 | |
| Cequr Corporation | $23.95 | 2022-2023 | Cequr Simplicity |
| Clarus Therapeutics INC. | $21.73 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.24 | 2024 | Gvoke Hypopen |
| Pacira Pharmaceuticals Incorporated | $19.31 | 2023 | Zilretta, Iovera |
| Tolmar, INC. | $17.13 | 2025 | Jatenzo |
| Eisai INC. | $16.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.49 | 2025 | Eliquis |
| Vertical Pharmaceuticals, LLC | $13.72 | 2024 | Relexxii |
| Exeltis, USA INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katay Bouttamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.